Cargando…
Assessment of a developed HPLC-MS/MS approach for determining plasma eupatorin in rats and its application in pharmacokinetics analysis
Eupatorin, a bioactive compound extracted from Java tea (Orthosiphon stamineus), possesses potent anti-cancer, anti-inflammatory and vasodilation activities. To date, no pharmacokinetics studies on eupatorin have yet been performed. Here, we established and validated a sensitive and selective LC-MS/...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Royal Society of Chemistry
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9056642/ https://www.ncbi.nlm.nih.gov/pubmed/35518153 http://dx.doi.org/10.1039/d0ra03350b |
_version_ | 1784697708976537600 |
---|---|
author | Feng, Rui Li, Luya Zhang, Xiaowei Zhang, Yuqian Chen, Yuting Feng, Xue Zhang, Lantong Zhang, Guohua |
author_facet | Feng, Rui Li, Luya Zhang, Xiaowei Zhang, Yuqian Chen, Yuting Feng, Xue Zhang, Lantong Zhang, Guohua |
author_sort | Feng, Rui |
collection | PubMed |
description | Eupatorin, a bioactive compound extracted from Java tea (Orthosiphon stamineus), possesses potent anti-cancer, anti-inflammatory and vasodilation activities. To date, no pharmacokinetics studies on eupatorin have yet been performed. Here, we established and validated a sensitive and selective LC-MS/MS (liquid chromatography-tandem mass spectrometry) approach for determining plasma eupatorin in rats. Chromatographic fractionation was conducted on a Wonda Cract ODS-2 C18 Column (4.6 mm × 150 mm, 5 μm) with a mobile phase containing aqueous 0.1% formic acid and acetonitrile using a flow rate of 0.8 ml min(−1). In multiple reaction monitoring mode, precursor-to-product ion transitions for quantification of eupatorin and the internal standard were set at 343.1 → 328.1 and 252.0 → 155.9, respectively. The intra- and inter-day precision and accuracy were found to be below 6.72% and within ±8.26% in rat plasma, respectively. Meanwhile, all values of the matrix effect, recovery and stability were within the accepted ranges. Furthermore, we carried out the pharmacokinetic analysis using the developed method. The pharmacokinetic study revealed that while the C(max) (maximum plasma concentration) of eupatorin and time for reaching the C(max) (T(max)) were 974.886 ± 293.898 μg L(−1) and 0.25 h, respectively, the half-life was 0.353 ± 0.026 h. This study will be of great significance to the research on the pharmacology, clinical pharmacy and drug action mechanism of eupatorin. |
format | Online Article Text |
id | pubmed-9056642 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | The Royal Society of Chemistry |
record_format | MEDLINE/PubMed |
spelling | pubmed-90566422022-05-04 Assessment of a developed HPLC-MS/MS approach for determining plasma eupatorin in rats and its application in pharmacokinetics analysis Feng, Rui Li, Luya Zhang, Xiaowei Zhang, Yuqian Chen, Yuting Feng, Xue Zhang, Lantong Zhang, Guohua RSC Adv Chemistry Eupatorin, a bioactive compound extracted from Java tea (Orthosiphon stamineus), possesses potent anti-cancer, anti-inflammatory and vasodilation activities. To date, no pharmacokinetics studies on eupatorin have yet been performed. Here, we established and validated a sensitive and selective LC-MS/MS (liquid chromatography-tandem mass spectrometry) approach for determining plasma eupatorin in rats. Chromatographic fractionation was conducted on a Wonda Cract ODS-2 C18 Column (4.6 mm × 150 mm, 5 μm) with a mobile phase containing aqueous 0.1% formic acid and acetonitrile using a flow rate of 0.8 ml min(−1). In multiple reaction monitoring mode, precursor-to-product ion transitions for quantification of eupatorin and the internal standard were set at 343.1 → 328.1 and 252.0 → 155.9, respectively. The intra- and inter-day precision and accuracy were found to be below 6.72% and within ±8.26% in rat plasma, respectively. Meanwhile, all values of the matrix effect, recovery and stability were within the accepted ranges. Furthermore, we carried out the pharmacokinetic analysis using the developed method. The pharmacokinetic study revealed that while the C(max) (maximum plasma concentration) of eupatorin and time for reaching the C(max) (T(max)) were 974.886 ± 293.898 μg L(−1) and 0.25 h, respectively, the half-life was 0.353 ± 0.026 h. This study will be of great significance to the research on the pharmacology, clinical pharmacy and drug action mechanism of eupatorin. The Royal Society of Chemistry 2020-08-28 /pmc/articles/PMC9056642/ /pubmed/35518153 http://dx.doi.org/10.1039/d0ra03350b Text en This journal is © The Royal Society of Chemistry https://creativecommons.org/licenses/by-nc/3.0/ |
spellingShingle | Chemistry Feng, Rui Li, Luya Zhang, Xiaowei Zhang, Yuqian Chen, Yuting Feng, Xue Zhang, Lantong Zhang, Guohua Assessment of a developed HPLC-MS/MS approach for determining plasma eupatorin in rats and its application in pharmacokinetics analysis |
title | Assessment of a developed HPLC-MS/MS approach for determining plasma eupatorin in rats and its application in pharmacokinetics analysis |
title_full | Assessment of a developed HPLC-MS/MS approach for determining plasma eupatorin in rats and its application in pharmacokinetics analysis |
title_fullStr | Assessment of a developed HPLC-MS/MS approach for determining plasma eupatorin in rats and its application in pharmacokinetics analysis |
title_full_unstemmed | Assessment of a developed HPLC-MS/MS approach for determining plasma eupatorin in rats and its application in pharmacokinetics analysis |
title_short | Assessment of a developed HPLC-MS/MS approach for determining plasma eupatorin in rats and its application in pharmacokinetics analysis |
title_sort | assessment of a developed hplc-ms/ms approach for determining plasma eupatorin in rats and its application in pharmacokinetics analysis |
topic | Chemistry |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9056642/ https://www.ncbi.nlm.nih.gov/pubmed/35518153 http://dx.doi.org/10.1039/d0ra03350b |
work_keys_str_mv | AT fengrui assessmentofadevelopedhplcmsmsapproachfordeterminingplasmaeupatorininratsanditsapplicationinpharmacokineticsanalysis AT liluya assessmentofadevelopedhplcmsmsapproachfordeterminingplasmaeupatorininratsanditsapplicationinpharmacokineticsanalysis AT zhangxiaowei assessmentofadevelopedhplcmsmsapproachfordeterminingplasmaeupatorininratsanditsapplicationinpharmacokineticsanalysis AT zhangyuqian assessmentofadevelopedhplcmsmsapproachfordeterminingplasmaeupatorininratsanditsapplicationinpharmacokineticsanalysis AT chenyuting assessmentofadevelopedhplcmsmsapproachfordeterminingplasmaeupatorininratsanditsapplicationinpharmacokineticsanalysis AT fengxue assessmentofadevelopedhplcmsmsapproachfordeterminingplasmaeupatorininratsanditsapplicationinpharmacokineticsanalysis AT zhanglantong assessmentofadevelopedhplcmsmsapproachfordeterminingplasmaeupatorininratsanditsapplicationinpharmacokineticsanalysis AT zhangguohua assessmentofadevelopedhplcmsmsapproachfordeterminingplasmaeupatorininratsanditsapplicationinpharmacokineticsanalysis |